This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read moreThis article explores the significant disparities between the US and Europe regarding orphan drugs a...
Read moreOur client required focused payer value messages for their PUMA product as payers were not recognizi...
Read moreOur client needed to understand the clinical and economic evidence requirements that drive payer dec...
Read moreOur client required focused payer value messages for their orphan drug as payers were not recognizin...
Read moreWe summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreOur client was seeking NICE approval for their ultra-orphan drug in an indication that was not well ...
Read more